Effects of Shenkangwan on renal expressions of angiotensin II and its type I receptor in rats with early diabetic nephropathy

• Published in: Nan fang yi ke da xue xue bao = Journal of Southern Medical University Vol. 30; no. 4; p. 805
• Main Authors: Long, Hai-bo, Niu, Hong-xin, Li, Xiao-yun, Xu, Zhao-zhong, Zhang, Hui, Zhong, Juan, Wei, Lian-bo
• Format: Journal Article
• Language: Chinese
• Published: China 01.04.2010
• Subjects: Angiotensin II - genetics; Angiotensin II - metabolism; Angiotensin II Type 1 Receptor Blockers - therapeutic use; Animals; Diabetic Nephropathies - drug therapy; Diabetic Nephropathies - metabolism; Drugs, Chinese Herbal - therapeutic use; Kidney - metabolism; Male; Phytotherapy; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1 - genetics; Receptor, Angiotensin, Type 1 - metabolism; RNA, Messenger - genetics; RNA, Messenger - metabolism
• ISSN: 1673-4254

To investigate the effects of Shenkangwan on the expressions of angiotensin II (AngII) and its type I receptor (AT(1)R) and the renalprotection mechanism of Shenkangwan in rats with early diabetic nephropathy (DN). The rat models of DN established by a single injection of streptozotocin were randomly divided into 4 groups, namely the model group, Shenkangwan treatment group, irbesartan treatment group, and Shenkangwan and irbesartan treatment group, with normal rats as the control. All the rats received daily gavage for 8 weeks. The urinary protein quality in 24 h and plasma and renal contents of AngII were measured. The expressions of AT1R at the protein and mRNA levels in the kidney tissues were measured by immunohistochemistry and reverse transcription-polymerase chain reaction, respectively. The pathological changes of the kidney were observed microscopically. In DN rats, Shenkangwan reduced the urinary protein quantity in 24 h and the contents of AngII in the plasma and kidney tissues, decreased the rena